Bosutinib hydrate (SKI606; KIN001160; SKI-606; KIN-001160; Bosulif), the mono-hydrated form of bosutinib, is a synthetic quinolone derivative and dual kinase inhibitor targeting both Abl and Src kinases with potential antineoplastic activity. Bosutinib was approved in 2012 for treating Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) in adult patients.

纯度：≥98%

CAS：918639-08-4